论文部分内容阅读
目的探讨血清人附睾蛋白4(HE4)、糖类抗原125(CA125)联合检测和ROMA风险评估对卵巢癌诊断的应用价值。方法用ELISA和化学发光免疫法检测血清HE4和CA125,比较各组检测结果、诊断的敏感性和特异性,用ROMA风险评估系统评估卵巢癌风险。结果血清HE4和CA125浓度卵巢癌组(46例)显著高于卵巢良性肿瘤组(56例)和健康对照组(56例)。对卵巢癌诊断的敏感性和特异性,血清HE4为73.9%和98.2%,CA125为78.3%和75.0%,联合检测为82.6%和92.9%。对卵巢良性肿瘤患者,未绝经者ROMA≥13.1%、绝经者ROMA≥27.7%时,卵巢癌发病的风险较高。结论血清HE4检测的敏感性不高,CA125检测的敏感性与特异性都不高,二者联合检测的敏感性与特异性都较高。二者联合检测并进行ROMA风险评估,可提高卵巢癌诊断的敏感性和特异性,对卵巢癌的早期诊断和鉴别有重要意义。
Objective To investigate the diagnostic value of serum human epididymal protein 4 (HE4), carbohydrate antigen 125 (CA125) combined with ROMA risk assessment in ovarian cancer. Methods The serum levels of HE4 and CA125 were detected by ELISA and chemiluminescence immunoassay. The sensitivity, specificity and specificity of the test results were compared. The ROMA risk assessment system was used to evaluate the risk of ovarian cancer. Results Serum concentrations of HE4 and CA125 in ovarian cancer group (46 cases) were significantly higher than those in benign ovarian tumor group (56 cases) and healthy control group (56 cases). Sensitivity and specificity for the diagnosis of ovarian cancer, serum HE4 was 73.9% and 98.2%, CA125 was 78.3% and 75.0%, the joint test was 82.6% and 92.9%. For patients with benign ovarian tumors, non-menopausal patients with ROMA ≥ 13.1%, menopausal patients with ROMA ≥ 27.7%, the higher the risk of ovarian cancer. Conclusion The sensitivity of HE4 detection is not high, and the sensitivity and specificity of detection of CA125 are not high. The detection sensitivity and specificity of both detection are high. The combination of the two and the ROMA risk assessment can improve the sensitivity and specificity of ovarian cancer diagnosis and is of great significance for the early diagnosis and differential diagnosis of ovarian cancer.